Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

United States

University of California San Francisco, San Francisco, California

Olive View-University of California Los Angeles Medical Center, Sylmar, California

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington